News

Alzamend Neuro sets trial dosage for AL001 lithium therapy

Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The identified dose is unlikely to require the type of intensive drug monitoring that has been a major hurdle to the…

Simufilam found safe in review of ongoing Alzheimer’s clinical trials

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by therapy developer…

Fujirebio seeks FDA approval of blood test for Alzheimer’s

Fujirebio Diagnostics asked the U.S. Food and Drug Administration (FDA) to approve its Alzheimer’s disease diagnostic blood test,  Lumipulse G pTau 217/β [beta]-Amyloid 1-42 Plasma Ratio. If approved, the test would be the first commercially available blood-based in vitro test in the U.S. to aid in diagnosing…

New partners team up for Phase 2 trial of novel lithium therapy AL001

Alzamend Neuro is partnering with Massachusetts General Hospital to conduct a Phase 2 clinical trial of AL001, an oral therapy being developed for dementia related to Alzheimer’s disease. The trial will compare the brain levels of AL001, a novel lithium-delivery system, with those of marketed lithium, in healthy…

Oral AMX0035 found to improve core Alzheimer’s-related biomarkers

Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial. “The results from this exploratory analysis suggest that AMX0035 engages important pathways implicated in the [development] of Alzheimer’s disease and other neurodegenerative…